eBook | Addressing controversies in breast cancer treatment

The last decade has seen breakthroughs in breast cancer treatment options including immune checkpoint inhibitors, PARP inhibitors and antibody drug conjugates. However, controversies remain over the best courses of treatment, whether that be solo or combination therapies, and whether or not breastfeeding after a breast cancer diagnosis is safe.  

In this eBook, gain access to peer-reviewed journal content and expert insights into possible synergistic relationships between treatments, complexities of adjuvant therapies and breastfeeding choices for cancer patients.

Highlights include:

• [CONFERENCE REPORT] Key insights from SABCS 2024
• [INTERVIEW] Breastfeeding choices for cancer patients: insights from the POSITIVE trial
• [COMMENTARY] Combining immunotherapy with PARP inhibitors. Is it possible to find the way through?
• [DRUG EVALUATION] Sacituzumab govitecan: past, present and future of a new antibody–drug conjugate and future horizon
• [META ANALYSIS] Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis
• [REVIEW] Current usage of pembrolizumab in triple negative breast cancer (TNBC)